1. Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease 
Jennifer Sung Whangbo, Haesook T. Kim, Sarah Nikiforow, John Koreth, Soomin Kim, Edwin P. Alyea, Philippe Armand, Corey Cutler, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz 
Biology of Blood and Marrow Transplantation 
Volume 24, Issue 3, Pages S70-S71 (March 2018)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Changes in entropy and clonality with low-dose IL-2. (A) Entropy in healthy donors vs cGVHD patients prior to IL-2 and at week 12 of IL-2 therapy. (B) Entropy and clonality in clinical responders. HD, healthy donor. Pre, pre-treatment. W12, week 12. *P < .05, **P < .005, n.s. not significant.
Biology of Blood and Marrow Transplantation  , S70-S71DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
Top 100 clones present after 12 weeks of IL-2 therapy. (A) Fraction of top 100 clones detected at Week 12 that are also detectable prior to IL-2 therapy. (B) Log base 2 of the ratio of productive frequency at Week 12:Pre-treatment of the top Treg clones detected at both baseline and Week 12. Pre, pre-treatment. W12, week 12. R, responders. NR, non-responders. **P < .005, ***P < .0001
Biology of Blood and Marrow Transplantation  , S70-S71DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
TCR overlap between Treg and Tcon clones before and after IL-2 therapy. Pre, pre-treatment. W12, week 12. HD, healthy donors. *P < .05.
Biology of Blood and Marrow Transplantation  , S70-S71DOI: ( /j.bbmt )
Copyright © Terms and Conditions